Patents by Inventor Paul A. W. Edwards

Paul A. W. Edwards has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Monoclonal antibody producing hybridoma and corresponding antibody specific for human breast fibroblast tumor antigen
    Patent number: 5003046
    Abstract: The invention concerns a novel lymphocyte hybridoma and an antibody which may be generated from the hybridoma. The hybridoma and antibody have the internal designation LICR-LON-Fib 75. The origin, method of preparation and uses are discussed. The antibody has particular application in the diagnosis and treatment of cancer of the breast. A particular therapeutic treatment comprises harvesting a sample of bone marrow from a patient, subjecting the patient to treatment adapted to kill cancerous material including that within the bone marrow (possibly including the normal differentiated haemopoietic cells of the marrow), subjecting some or all of the sample to cytotoxic treatment with the antibody (or a toxin conjugate thereof) adapted to kill cancerous cell lines while leaving viable colony-forming units of bone marrow, and reintroducing the treated sample material to the blood stream of the patient.
    Type: Grant
    Filed: December 23, 1987
    Date of Patent: March 26, 1991
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Alexander M. Neville, Christopher S. Foster, Paul A. W. Edwards, Robert A. J. McIlhinney
  • Novel monoclonal hybridoma and corresponding antibody
    Patent number: 4731238
    Abstract: The invention concerns a novel lymphocyte hybridoma and an antibody which may be generated from the hybridoma. The hybridoma and antibody have the internal designation LICR-LON-Fib 75. The origin, method of preparation and uses are discussed. The antibody has particular application in the diagnosis and treatment of cancer of the breast. A particular therapeutic treatment comprises harvesting a sample of bone marrow from a patient, subjecting the patient to treatment adapted to kill cancerous material including that within the bone marrow (possibly including the normal differentiated haemopoietic cells of the marrow), subjecting some or all of the sample to cytotoxic treatment with the antibody (or a toxin conjugate thereof) adapted to kill cancerous cell lines while leaving viable colony-forming units of bone marrow, and reintroducing the treated sample material to the blood stream of the patient.
    Type: Grant
    Filed: December 5, 1983
    Date of Patent: March 15, 1988
    Assignee: Research Corporation Technologies, Inc.
    Inventors: Alexander M. Neville, Christopher S. Foster, Paul A. W. Edwards, Robert A. J. McIlhinney